日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition

成纤维细胞活化蛋白靶向放射治疗诱导免疫原性肿瘤微环境并增强 PD-1 免疫检查点抑制的疗效

Dirk Zboralski, Frank Osterkamp, Esben Christensen, Anne Bredenbeck, Anne Schumann, Aileen Hoehne, Eberhard Schneider, Matthias Paschke, Jan Ungewiss, Christian Haase, Liliane Robillard, Andrew D Simmons, Thomas C Harding, Minh Nguyen

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

FAP-2286 用于成纤维细胞活化蛋白靶向放射性核素显像和治疗的临床前评估

Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck, Anne Schumann, Minh Nguyen, Eberhard Schneider, Jan Ungewiss, Matthias Paschke, Christian Haase, Jan L von Hacht, Tanya Kwan, Kevin K Lin, Jan Lenore, Thomas C Harding, Jim Xiao, Andrew D Simmons, Ajay-Mohan Mohan, Nicola Beindorff, Ulrich Reineke, Chr

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

BET、SRC 和 BCL2 家族抑制剂与 PARP 抑制剂在卵巢癌中具有协同药物组合作用

Goldie Y L Lui, Reid Shaw, Franz X Schaub, Isabella N Stork, Kay E Gurley, Caroline Bridgwater, Robert L Diaz, Rachele Rosati, Hallie A Swan, Tan A Ince, Thomas C Harding, Vijayakrishna K Gadi, Barbara A Goff, Christopher J Kemp, Elizabeth M Swisher, Carla Grandori

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

循环肿瘤 DNA 分析揭示肺癌患者 EGFR 抑制剂耐药机制的异质性

Jacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, Mohammad S Esfahani, Aaron M Newman, Henry J Haringsma, David M Kurtz, Henning Stehr, Florian Scherer, Chris A Karlovich, Thomas C Harding, Kathleen A Durkin, Gregory A Otterson, W Thomas Purcell, D Ross Camidge, Jonathan W Goldman, Lecia V Sequ